WuXi Vaccines

Name

WuXi Vaccines

Legal name

WuXi Vaccines (Hong Kong) Limited

Website

https://wuxivaccines.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Vaccine Contract Development and Manufacturing (CDMO) Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccine Quality, Safety & Pharmacovigilance (HLAIAEAL)

Keywords

• Vaccine contract manufacturing
• Biologics CDMO services
• Prophylactic antibody development
• GMP vaccine production
• Microbial fermentation services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Fee-for-service CDMO model providing end-to-end development and manufacturing services for vaccine and prophylactic antibody products. Revenue is project-based, typically with long-term manufacturing agreements such as the 20-year vaccine supply contract valued at approximately USD $3 billion in Ireland.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

WuXi Vaccines is a global contract development and manufacturing organization (CDMO) providing end-to-end vaccine and prophylactic antibody development and manufacturing services across multiple modalities — mammalian (mAb, recombinant protein, nanoparticle, VLP), microbial (recombinant protein, VLP, OMV, live-attenuated), viral (live-attenuated and viral-vectored), nucleic acid, and conjugated vaccines. Services span cell line development, upstream and downstream process development, cGMP drug substance and drug product manufacturing, fill-finish, analytical testing, and late-stage development/commercialization from GMP-certified facilities in Suzhou (China) and Singapore.

Product overview

WuXi Vaccines is a global contract development and manufacturing organization (CDMO) providing integrated vaccine and prophylactic antibody development and manufacturing platforms. The company offers end-to-end services across multiple modalities including mammalian (mAb, recombinant protein, nanoparticle, VLP), microbial (recombinant protein, VLP, OMV, live-attenuated), and viral (live-attenuated and viral-vectored) platforms. The portfolio encompasses Cell Line Development, Upstream Process Development, Downstream Process Development, Final Vaccine Drug Product Development, cGMP Manufacturing, Late Stage Development and Commercialization, and Analytical Testing services. WuXi Vaccines leverages capabilities across global GMP-certified facilities in China (Suzhou) and Singapore to provide partners with integrated development and manufacturing services tailored to innovative vaccine and prophylactic antibody projects.

Differentiator

Problem solved

Functional benefit

Products and services

• Final Vaccine Drug Product Development Industry-leading final vaccine and prophylactic antibody product development services including clinical and commercial formulations, liquid, frozen, lyophilized, emulsion, and suspension dosage forms with multiple container closure systems (vials and pre-filled syringes). For vaccine developers and pharmaceutical companies seeking end-to-end CDMO support.
• Late Stage Development and Commercialization Single-source high-quality late-phase development and manufacturing services designed to accelerate products through BLA filing in as little as 14 months, including assay and formulation development, optimization, characterization, validation, and global GMP manufacturing supply network. For vaccine developers approaching regulatory submission and commercial launch.
• Cell Line Development Mammalian cell line development providing expert guidance, vetted cell line technology, and efficient development timelines for antibodies, recombinant protein vaccines, and viral-based vaccines with GMP cell banking and cell line characterization. For vaccine and biotech developers.
• Upstream Process Development State-of-the-art cell culture development labs and non-GMP pilot plant specializing in process development, characterization, validation and scale-up to establish successful cGMP clinical and commercial manufacturing. For vaccine developers and pharmaceutical companies.
• Downstream Process Development State-of-the-art purification process development, process scale-up, process characterization, and technology transfer to cGMP production using various chromatographic resins including affinity, ion exchange, hydrophobic interaction, hydroxyapatite, and mix-mode. For vaccine developers requiring protein purification development.
• cGMP Manufacturing (Microbial) cGMP manufacturing of bulk and final vaccine product for preclinical, clinical, and commercial supply including drug substance (BSL-1/BSL-2) and drug product manufacturing with RABS, oRABS and isolator-based filling lines. For vaccine developers and pharmaceutical companies requiring GMP production.
• Viral Vaccines cGMP Manufacturing Extensive capabilities in development and GMP manufacturing of live-attenuated viral vaccines and viral vectored vaccines in BSL-2 facilities using single-use bioreactors up to 500L with oRABS and isolator technology for fill and finish. For vaccine developers seeking viral vaccine production.
• Microbial Services Development Comprehensive end-to-end microbial production system from strain development to CMC dossier and regulatory support including E. coli and yeast host systems, expression vector construction, and process development for nucleic acid or protein-based vaccines. For vaccine developers using microbial expression systems.
• Analytical Testing (Mammalian) Comprehensive analytical services for vaccines (VLP and recombinant protein subunit) and prophylactic antibodies supporting developability studies, in-process analysis, cell line, process development, formulation development, product characterization, lot release, stability studies, and IND/BLA/MAA/EUA dossier preparation. For vaccine developers and pharmaceutical companies.
• Microbial Analytical Testing Dedicated microbial analytical testing services including HPLC/CE, biochemical, compendial, microbiology, raw material testing, and bioassays with GMP DS/DP release and stability studies. For vaccine developers using microbial expression systems.
• Viral Vaccine Analytical Testing Comprehensive viral vaccine analytical testing capabilities including infectivity assays, potency testing, safety testing, and engineered analytical cell line development with 200+ in vitro cell models of pathogenesis. For vaccine developers with viral vaccine candidates.
• Viral Vectors for Vaccines Viral vaccine production platforms supporting AdV, HSV, VSV, Vaccinia Virus, and MV with in-house producer cell lines, cell/virus banking, process development, DS and DP manufacturing, lot release and regulatory support. For vaccine developers using viral vector platforms.
• Viral Vaccines Process Development Virus production cell line development and process platforms leveraging HEK 293 cells for optimal performance with commercial media and chemically defined media preferred processes. For vaccine developers working on viral vaccine candidates.
• Microbial Modalities Comprehensive CMC development and GMP manufacturing services for recombinant proteins (subunit vaccines), VLP, OMV, and nucleic acid-based vaccines produced via microbial fermentation with BSL-1 and BSL-2 facilities. For vaccine developers using microbial platforms.

Quantifiable outcome

• 550+ million doses delivered globally
• +3 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Delonix BioworkscoreStrategic or Co-development Partner · 21 April 2025Strategic partnership to accelerate global application of OMV Plus technology for bacterial vaccines. WuXi Vaccines provides integrated development and manufacturing capabilities for Delonix's OMV vaccine platform. In 2024 collaboration, GMP-scale production achieved within 10 months with yields exceeding 1 million doses per 100L batch at <$1 per dose cost. Addressing antimicrobial resistance through innovative bacterial vaccines.
• Instituto ButantancoreStrategic or Co-development Partner · 12 February 2025WuXi Vaccines provides end-to-end manufacturing services for Instituto Butantan's dengue vaccine (Butantan-DV). The partnership aims to deliver several million doses to protect Brazil's population from dengue. Facilities have received ANVISA GMP certification for both drug substance (MFG23) and drug product (DP17) manufacturing.
• Fundação ButantancoreStrategic or Co-development Partner · 12 February 2025WuXi Vaccines provides end-to-end manufacturing services for dengue vaccine under commercial manufacturing agreement with Instituto Butantan and Fundação Butantan.
• Delonix BioworkscoreStrategic or Co-development Partner · 25 January 2024Initial agreement to accelerate development and manufacturing of Delonix's innovative bacterial vaccines. WuXi Vaccines provides technical expertise, regulatory experience, and GMP manufacturing capacity.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Catalent: Global biologics and vaccine CDMO providing mammalian and microbial development, fill-finish, and commercial manufacturing. Highly comparable as a full-service vaccine CDMO serving pharma and biotech clients with multi-modality platforms.
• Lonza: Largest global CDMO with mammalian and microbial biologics manufacturing, including vaccine and viral vector capabilities. Comparable as a multi-modality vaccine CDMO with regulatory-grade facilities across Europe and the US.
• AGC Biologics: Global CDMO providing mammalian and microbial biologics, including vaccine and viral vector manufacturing. Comparable as a multi-modality CDMO targeting similar biotech and pharma customers with end-to-end development services.
• Samsung Biologics: Asia-based biologics CDMO with large-scale mammalian manufacturing and expanding vaccine and viral vector capabilities. Comparable in modality coverage and global client base, and a direct competitor for APAC-headquartered biotech outsourcing.
• Emergent BioSolutions: Vaccine and biologics CDMO with established contract manufacturing services and BSL-2/3 facilities. Comparable as a dedicated vaccine manufacturer serving government and pharma clients through long-term supply agreements.
• IDT Biologika: European vaccine and biopharmaceutical CDMO offering microbial and cell-culture based vaccine development and manufacturing. Comparable as a dedicated vaccine contract manufacturer targeting similar biotech and government clients.

Broad incumbents

• WuXi Biologics: Parent company of WuXi Vaccines and a global biologics CDMO leader. Comparable as the closest corporate and operational peer; shares platforms, regulatory systems, and management infrastructure with WuXi Vaccines.
• Thermo Fisher Scientific (Patheon): Operates a biologics CDMO network (branded as Patheon) covering mammalian, microbial, and viral vector services plus fill-finish. Comparable as a broad incumbent offering overlapping vaccine CDMO capabilities within a much wider pharma services portfolio.
• Boehringer Ingelheim BioXcellence: Biologics contract manufacturing arm of Boehringer Ingelheim offering mammalian and microbial services, including vaccine process development and commercial supply. Comparable as a full-service vaccine/biologics CDMO within a larger pharma organization.

Regional players

• Serum Institute of India: World's largest vaccine manufacturer by dose volume with extensive microbial and viral vaccine production. Comparable in scale and vaccine modality breadth, though primarily a product manufacturer rather than a pure CDMO; relevant as a regional capacity competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wuxi-vaccines

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi Vaccines